MedTrace Logo

Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

NCT02156960 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-10-22

No results posted yet for this study

Summary

It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.

Conditions

Interventions

DRUG

Denosumab treatment in osteoporotic patients

To examine the effectiveness of denosumab in osteoporotic patients

DRUG

Teriparatide treatment in osteoporotic patients

To examine the effectiveness of teriparatide in osteoporotic patients

DRUG

Denosumab and teriparatide treatment in osteoporotic patients

To examine the effectiveness of denosumab and teriparatide in osteoporotic patients

Sponsors & Collaborators

  • Shinshu University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
1 Year
Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-05-31
Completion
2022-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02156960 on ClinicalTrials.gov